InvestorsHub Logo
Followers 0
Posts 88
Boards Moderated 0
Alias Born 03/27/2017

Re: None

Friday, 06/16/2017 4:48:00 PM

Friday, June 16, 2017 4:48:00 PM

Post# of 106839
Tomas suggests that they will not or cannot invest more money into dealing with the FDA. If that is really true, it implies that GACP has either pulled out of USRM or is now calling the tune financially and wants its money invested in clinics, not myocell development. Either way, I would not be surprised to see a company with deeper pockets try to acquire USRM (or its intellectual property rights) at a low-ball price now.